

Freedom of Information Act 2000**The Royal Cornwall Hospitals NHS Trust Response to Information request****Date Request Received: 12th February 2025 FOI Ref No 27716****Requested Information:**

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage) :

- Avelumab + Axitinib
- Axitinib
- Cabozantinib
- Everolimus
- Lenvatinib + Everolimus
- Lenvatinib + Pembrolizumab
- Nivolumab monotherapy
- Nivolumab + Cabozantinib
- Nivolumab + Ipilimumab
- Pazopanib
- Pembrolizumab monotherapy
- Pembrolizumab + Axitinib
- Radiotherapy only
- Sunitinib
- Temsirolimus
- Tivozanib
- Other active systemic anti-cancer therapy
- Palliative care only

Q2. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:

- Avelumab + Axitinib (Bavencio + Inlyta)
- Cabozantinib (Cometriq)
- Nivolumab (Opdivo)
- Nivolumab + Cabozantinib (Opdivo + Cometriq)
- Nivolumab + Ipilimumab (Opdivo + Yervoy)
- Lenvatinib + Pembrolizumab + (Kisplyx + Keytruda)

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

- Nivolumab (monotherapy)
- Nivolumab + Ipilimumab
- Nivolumab + Cabozantinib
- Avelumab + Axitinib
- Lenvatinib + Pembrolizumab + (Kisplyx + Keytruda)

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

Response:

Data for 1st Oct 2024 to 31st Dec 2024

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage) :

- Avelumab + Axitinib 3
- Axitinib 1
- Cabozantinib 11
- Everolimus 0
- Lenvatinib + Everolimus 4
- Lenvatinib + Pembrolizumab 10
- Nivolumab monotherapy 9 (7 of these were maintenance monotherapy following ipilimumab/nivolumab induction)
- Nivolumab + Cabozantinib 5
- Nivolumab + Ipilimumab 0
- Pazopanib 2
- Pembrolizumab monotherapy 12
- Pembrolizumab + Axitinib 0
- Radiotherapy only 1
- Sunitinib 0
- Temsirolimus 0
- Tivozanib 0
- Other active systemic anti-cancer therapy 2
- Palliative care only 0

Q2. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:

Information Governance

Version No: 1

Review Date: 2028

- Avelumab + Axitinib (Bavencio + Inlyta) 3
- Cabozantinib (Cometriq) 5
- Nivolumab (Opdivo) 7
- Nivolumab + Cabozantinib (Opdivo + Cometriq) 5
- Nivolumab + Ipilimumab (Opdivo + Yervoy) 0
- Lenvatinib + Pembrolizumab + (Kisplyx + Keytruda) 10

Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for Renal Cell Carcinoma?

- Nivolumab (monotherapy) 0
- Nivolumab + Ipilimumab 0
- Nivolumab + Cabozantinib 2
- Avelumab + Axitinib 0
- Lenvatinib + Pembrolizumab + (Kisplyx + Keytruda) 1

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q4. In the last 3 months, how many patients have undergone full or partial nephrectomy (any of the following OPCS codes M02.1, M02.2, M02.3, M02.4, M02.5, M03.1, M03.9, M04.2, M10.1 or M10.4)?

16 patients in total underwent full or partial nephrectomy at Royal Cornwall Hospitals Trust for all indications.

13 of these were for cancer treatments and an additional 9 RCHT cancer patients were treated at different trusts.

Attachment(s):

None

Date Response sent: